Division of Cardiology, Department of Medical Sciences, 'Città della Salute e della Scienza' Hospital, University of Turin, Torino, Italy.
Division of Cardiology, Department of Medical Sciences, 'Città della Salute e della Scienza' Hospital, University of Turin, Torino, Italy
Europace. 2016 May;18(5):638-47. doi: 10.1093/europace/euv368. Epub 2016 Feb 8.
Catheter ablation of atrial fibrillation (AFCA) is a widely recommended treatment for symptomatic atrial fibrillation (AF) patients refractory to pharmacological treatment. Catheter ablation of AF is becoming a therapeutic option also among patients with chronic heart failure (CHF), on top of optimal medical treatment, being this arrhythmia related to a higher risk of death and/or symptom's worsening. In fact, in this setting, clinical evidences are continuously increasing. The present systematic review pools all published experiences concerning AFCA among CHF patients, or patients with structural cardiomyopathies, in order to summarize procedural safety and efficacy in this specific population. Moreover, the effects of AFCA on functional class and quality of life and the different procedural protocols available are discussed. The present work, therefore, attempts to provide an evidence-based clinical perspective to optimize clinical indication and tailor procedural characteristics and endpoints to patients affected by CHF referred for AFCA.
房颤导管消融术(AFCA)是一种广泛推荐的治疗方法,适用于对药物治疗反应不佳的有症状房颤(AF)患者。除了最佳药物治疗外,AFCA 也成为慢性心力衰竭(CHF)患者的治疗选择,因为这种心律失常与更高的死亡和/或症状恶化风险相关。事实上,在这种情况下,临床证据不断增加。本系统综述汇集了所有关于 CHF 患者或结构性心肌病患者中 AFCA 的已发表经验,以总结该特定人群中的程序安全性和疗效。此外,还讨论了 AFCA 对心功能分级和生活质量的影响,以及可用的不同程序方案。因此,本研究旨在为优化临床适应证提供循证临床观点,并根据接受 AFCA 的 CHF 患者的特点和终点来调整程序特征。